SCHEMBL1322020

SCHEMBL1322020

COc1cccc(C(=O)NCCN2CCN(c3ccc(Cl)cc3)CC2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 16/20 1.00
DRD2 P14416 7/20 1.00
CYP1A2 P05177 1/20 1.00
CYP3A4 P08684 1/20 1.00
CYP2D6 P10635 1/20 1.00
MAPT P10636 1/20 1.00
PMP22 Q01453 1/20 1.00
CYP2C9 P11712 1/20 0.70
CYP2C19 P33261 1/20 0.70
HTR1A P08908 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6403181 0.83 DRD4 (0.72) DRD4DRD2CYP1A2CYP3A4CYP2D6
SCHEMBL6402004 0.83 CCR3 (0.82) DRD4DRD2CYP1A2CYP3A4CYP2D6
SCHEMBL11712058 0.83 DRD4 (0.71) DRD4DRD2CYP1A2CYP3A4CYP2D6
SCHEMBL15822962 0.82 CYP2C19 (1.00) DRD4DRD2CYP1A2CYP3A4CYP2D6
SCHEMBL30098940 0.82 CYP2C19 (1.00) DRD4DRD2CYP1A2CYP3A4CYP2D6
Hydrochloric Acid SCHEMBL6397461 0.82 CCR3 (0.81) DRD4DRD2CYP1A2CYP3A4CYP2D6
SCHEMBL7596469 0.79 DRD4 (0.68) DRD4DRD2CYP1A2CYP3A4CYP2D6
Hydrochloric Acid SCHEMBL6396151 0.78 DRD4 (0.67) DRD4DRD2CYP1A2CYP3A4CYP2D6
SCHEMBL4521840 0.78 DRD4 (0.77) DRD4DRD2HTR1A
SCHEMBL9287641 0.77 DRD2 (0.74) DRD4DRD2CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119842625-A Cell line for stably expressing orthogonal aminoacyl tRNA synthetase/tRNA pair 浙江大学 2025-04-18 CN claimed
CN-118421507-A Application of medical cell CMU-Pb-12 combined dexamethasone in preparation of psoriasis prevention and treatment drugs 广东行海生物科技有限公司 2024-08-02 CN claimed
US-20260139009-A1 PREFUSION-STABILIZED CMV GB PROTEINS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2026-05-21 US disclosed
US-20260062742-A1 RECOMBINANT LIGASES AND USES THEREOF SINGULAR GENOMICS SYSTEMS INC (US) 2026-03-05 US disclosed
CN-119842625-A Cell line for stably expressing orthogonal aminoacyl tRNA synthetase/tRNA pair 浙江大学 2025-04-18 CN disclosed
EP-4497741-A1 ORGANIC FERTILIZER FROM STERILIZED AND DRIED INSECT FRASS, ESPECIALLY FROM HERMETIA ILLUCENS, ITS APPLICATIONS AND METHODS OF FERTILIZATION AND IMPROVEMENT OF SOIL MOISTURE USING IT HiProMine S.A. (PL) 2025-01-29 EP disclosed
CN-119192113-A Pleuromutilin derivative and preparation method and application thereof 西华大学 2024-12-27 CN disclosed
US-20240309211-A1 Composite Wood Board KNAUF INSULATION SPRL (BE) 2024-09-19 US disclosed
CN-118421507-A Application of medical cell CMU-Pb-12 combined dexamethasone in preparation of psoriasis prevention and treatment drugs 广东行海生物科技有限公司 2024-08-02 CN disclosed
CN-118421507-A Application of medical cell CMU-Pb-12 combined dexamethasone in preparation of psoriasis prevention and treatment drugs 广东行海生物科技有限公司 2024-08-02 CN disclosed
CN-118421507-A Application of medical cell CMU-Pb-12 combined dexamethasone in preparation of psoriasis prevention and treatment drugs 广东行海生物科技有限公司 2024-08-02 CN disclosed
US-20160361319-A1 METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN AGGREGATION UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2016-12-15 US disclosed
US-9452171-B2 Methods of treating disorders associated with protein aggregation University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2016-09-27 US disclosed
US-20150265626-A1 METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN AGGREGATION UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2015-09-24 US disclosed
US-9072772-B2 Methods of treating disorders associated with protein aggregation University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2015-07-07 US disclosed
US-20140331341-A1 AUTOMATED HIGH-CONTENT LIVE ANIMAL DRUG SCREENING USING C. ELEGANS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2014-11-06 US disclosed
US-20140047569-A9 Methods of Treating Disorders Associated with Protein Aggregation UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2014-02-13 US disclosed
US-20130024953-A1 Methods of Treating Disorders Associated with Protein Aggregation UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2013-01-24 US disclosed
US-8058243-B2 Method for treating a brain cancer with ifenprodil HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) 2011-11-15 US disclosed
US-20090076019-A1 METHODS FOR TREATING NEUROLOGICAL DISORDERS OR DAMAGE MOUNT SINAI HOSPITAL (CA) 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160361319-A1 METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN AGGREGATION HTT, ATIC, API5 DRD4 3976/4885DRD2 3847/4885CYP1A2 2656/4885
US-20140047569-A9 Methods of Treating Disorders Associated with Protein Aggregation HTT, ATIC, API5 DRD4 3976/4885DRD2 3847/4885CYP1A2 2656/4885
US-20130024953-A1 Methods of Treating Disorders Associated with Protein Aggregation HTT, ATIC, API5 DRD4 3976/4885DRD2 3847/4885CYP1A2 2656/4885
US-20260062742-A1 RECOMBINANT LIGASES AND USES THEREOF LIG3, LIG1, LIG4 DRD4 3059/4885DRD2 3476/4885CYP1A2 3565/4885
US-20260139009-A1 PREFUSION-STABILIZED CMV GB PROTEINS H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GHDC, IGF2BP3 DRD4 2969/4885DRD2 2804/4885CYP1A2 4845/4885
US-20150265626-A1 METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN AGGREGATION HTT, ATIC, API5 DRD4 3976/4885DRD2 3847/4885CYP1A2 2656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.